EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TNA‐Mediated Antisense Strategy to Knockdown Akt Genes for Triple‐Negative Breast Cancer Therapy

Pan Li, Shixue Zheng, Hoi Man Leung, Ling Sum Liu, Tristan Juin Han Chang, Alishba Maryam, Fei Wang, Y Rebecca Chin, Pik Kwan Lo iD

Small Methods · 2024

DOI: 10.1002/smtd.202400291 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small Methods, 2024. Verfasst von Pan Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and State Key Laboratory of Marine Pollution, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong SAR, P. R. Ch…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health and Medical Research Fund, Hong Kong Research Grants Council, Science and Technology Innovation Committee of Shenzhen Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple‐negative breast cancer (TNBC) remains a significant challenge in terms of treatment, with limited efficacy of chemotherapy due to side effects and acquired drug resistance. In this study, a threose nucleic acid (TNA)‐mediated antisense approach is employed to target therapeutic Akt genes for TNBC therapy. Specifically, two new TNA strands (anti‐Akt2 and anti‐Akt3) are designed and synthesized that specifically target Akt2 and Akt3 mRNAs. These TNAs exhibit exceptional enzymatic resistance, high specificity, enhance binding affinity with their target RNA molecules, and improve cellular uptake efficiency compared to natural nucleic acids. In both 2D and 3D TNBC cell models, the TNAs effectively inhibit the expression of their target mRNA and protein, surpassing the effects of scrambled TNAs. Moreover, when administered to TNBC‐bearing animals in combination with lipid nanoparticles, the targeted anti‐Akt TNAs lead to reduced tumor sizes and decreased target protein expression compared to control groups. Silencing the corresponding Akt genes also promotes apoptotic responses in TNBC and suppresses tumor cell proliferation in vivo. This study introduces a novel approach to TNBC therapy utilizing TNA polymers as antisense materials. Compared to conventional miRNA‐ and siRNA‐based treatments, the TNA system holds promise as a cost‐effective and scalable platform for TNBC treatment, owing to its remarkable enzymatic resistance, inexpensive synthetic reagents, and simple production procedures. It is anticipated that this TNA‐based polymeric system, which targets anti‐apoptotic proteins involved in breast tumor development and progression, can represent a significant advancement in the clinical development of effective antisense materials for TNBC, a cancer type that lacks effective targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsProto-Oncogene Proteins c-aktHumansFemaleAnimalsCell Line, TumorMiceCell ProliferationApoptosisNanoparticlesGene Knockdown TechniquesXenograft Model Antitumor AssaysGene Expression Regulation, NeoplasticLiposomes

Stichwörter der Autor:innen

AKTantisense oligonucleotidesgene silencingthreose nucleic acidtriple‐negative breast cancer

Substanzen

Proto-Oncogene Proteins c-aktAKT3 protein, humanAKT2 protein, humanLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Department of Chemistry and State Key Laboratory of Marine Pollution, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong SAR, P. R. China.
  • Tung Biomedical Sciences Centre, Department of Biomedical Sciences, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong SAR, P. R. China.
  • Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, White City Campus, Wood Lane, London, W12 0BZ, U.K.
  • The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, P. R. China.
  • Key Laboratory of Biochip Technology, Biotech, and Health Care, Shenzhen Research Institute of City University of Hong Kong, Shenzhen, 518057, P. R. China.

ORCID-Profile: Pik Kwan Lo

Förderung

  • Health and Medical Research Fund
  • Hong Kong Research Grants Council
  • Science and Technology Innovation Committee of Shenzhen Municipality
  • City University of Hong Kong
  • National Science Foundation of China
  • SKLMP Seed Collaborative Research Fund
  • Dongguan Science and Technology of Social Development Program
  • National Natural Science Foundation of China

Zitieren

APA

Li, P., Zheng, S., Leung, H. M., Liu, L. S., Chang, T. J. H., Maryam, A., Wang, F., Chin, Y. R., & Lo, P. K. (2024). TNA‐Mediated Antisense Strategy to Knockdown Akt Genes for Triple‐Negative Breast Cancer Therapy. Small Methods. https://doi.org/10.1002/smtd.202400291

Vancouver

Li P, Zheng S, Leung HM, Liu LS, Chang TJH, Maryam A, et al. TNA‐Mediated Antisense Strategy to Knockdown Akt Genes for Triple‐Negative Breast Cancer Therapy. Small Methods. 2024. doi:10.1002/smtd.202400291

BibTeX
@article{Li2024,
  author = {Li, Pan and Zheng, Shixue and Leung, Hoi Man and Liu, Ling Sum and Chang, Tristan Juin Han and Maryam, Alishba and Wang, Fei and Chin, Y Rebecca and Lo, Pik Kwan},
  title = {TNA‐Mediated Antisense Strategy to Knockdown Akt Genes for Triple‐Negative Breast Cancer Therapy},
  journal = {Small Methods},
  year = {2024},
  doi = {10.1002/smtd.202400291}
}
Kostenlos starten →